Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hansoh Forms $1.5 Billion Partnership with Atomwise, an AI Drug Discovery Company

publication date: Sep 12, 2019

Hansoh Pharma of China announced a blockbuster $1.5 billion small molecule drug discovery collaboration with Atomwise, a San Francisco AI company. Atomwise will use its structure-based drug discovery programs to identify drug candidates for up to eleven target proteins in multiple therapeutic areas. Hansoh will make payments to Atomwise and hold global rights to any products, though Atomwise will receive royalties and participate in any sales or licensings. Hansoh, which completed a $1 billion IPO on the Hong Kong Exchange in June, is headquartered in Lianyuangang, Jiangsu Province. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital